Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (21-30 of 250) with videos related to

Pageof 25
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM|September 5, 2023
Impact of Prolonged Ischemia on the Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1)Angels Barberà, Juan González, Montserrat Martin, et al.
European Journal of Haematology|February 19, 2015
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or olderSusana Vives, Albert Oriol, Sònia Piernas, et al.
The Journal of Clinical Endocrinology and Metabolism|July 21, 2005
Serum pepsinogen I: an early marker of pernicious anemia in patients with type 1 diabetesNúria Alonso, M Luisa Granada, Isabel Salinas, et al.
Experimental Hematology|September 2, 2009
Metabolic fingerprinting of fresh lymphoma samples used to discriminate between follicular and diffuse large B-cell lymphomasIgnasi Barba, Carolina Sanz, Angels Barbera, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|March 6, 2020
The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample OverfixationAngels Barberà, Ruth Marginet Flinch, Montserrat Martin, et al.
European Journal of Haematology|May 2, 2021
Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myelomaGladys Ibarra, Marta Peña, Laura Abril, et al.
Medicina Clinica|October 18, 2003
[Reasons for not carrying out stem cell transplantation in patients referred to a transplant unit]Juan Manuel Sancho, Josep María Ribera, Albert Oriol, et al.
Cancers|November 25, 2023
Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational StudyGemma Garrido-Alejos, Guillem Saborit-Canals, Laura Guarga, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2019
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?Susanna Gassiot, Yolanda González, Mireia Morgades, et al.
International Journal of Hematology|December 7, 2007
Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapyJosé-Tomás Navarro, Josep-Maria Ribera, Albert Oriol, et al.
Pageof 25

Showing results (21-30 of 250) with videos related to

Sort By:
Pageof 25
Applied Immunohistochemistry & Molecular Morphology : AIMM|September 5, 2023
Impact of Prolonged Ischemia on the Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1)Angels Barberà, Juan González, Montserrat Martin, et al.
European Journal of Haematology|February 19, 2015
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or olderSusana Vives, Albert Oriol, Sònia Piernas, et al.
The Journal of Clinical Endocrinology and Metabolism|July 21, 2005
Serum pepsinogen I: an early marker of pernicious anemia in patients with type 1 diabetesNúria Alonso, M Luisa Granada, Isabel Salinas, et al.
Experimental Hematology|September 2, 2009
Metabolic fingerprinting of fresh lymphoma samples used to discriminate between follicular and diffuse large B-cell lymphomasIgnasi Barba, Carolina Sanz, Angels Barbera, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|March 6, 2020
The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample OverfixationAngels Barberà, Ruth Marginet Flinch, Montserrat Martin, et al.
European Journal of Haematology|May 2, 2021
Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myelomaGladys Ibarra, Marta Peña, Laura Abril, et al.
Medicina Clinica|October 18, 2003
[Reasons for not carrying out stem cell transplantation in patients referred to a transplant unit]Juan Manuel Sancho, Josep María Ribera, Albert Oriol, et al.
Cancers|November 25, 2023
Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational StudyGemma Garrido-Alejos, Guillem Saborit-Canals, Laura Guarga, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2019
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?Susanna Gassiot, Yolanda González, Mireia Morgades, et al.
International Journal of Hematology|December 7, 2007
Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapyJosé-Tomás Navarro, Josep-Maria Ribera, Albert Oriol, et al.
Pageof 25